GlassScriptPhysician profile
Adrian L Carter
NPI 1023002250
$5,088.85
in general payments reported to CMS, 2019-2025
31 companies · $1,988 in 2025
The $1,988 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $70.95 · 2021: $108 · 2022: $287 · 2023: $1,083 · 2024: $1,437 · 2025: $1,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,463 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,463.17 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $884.64 | 2020-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $869.56 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $863.69 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $333.88 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $318.24 | 2019-2025 | |
| Novo Nordisk INC | $216.60 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $186.23 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Eisai INC. | $167.56 | 2025 | |
| Novartis Pharmaceuticals Corporation | $159.95 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $148.42 | 2023-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $112.60 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $109.27 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $90.57 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $88.89 | 2023-2024 | Gemtesa |
| Edwards Lifesciences Corporation | $79.79 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $76.71 | 2023-2025 | Rexulti |
| Medtronic USA, INC. | $52.36 | 2019 | |
| Phathom Pharmaceuticals, INC. | $38.39 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $36.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.05 | 2023-2025 | Jardiance |
| Mylan Specialty L.P. | $29.42 | 2024 | Yupelri |
| Insulet Corporation | $25.88 | 2025 | Omnipod |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.44 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $23.38 | 2023 | Ingrezza |
| Viatris Specialty LLC | $20.54 | 2025 | Yupelri |
| Corium, LLC | $19.94 | 2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $19.02 | 2024 | Austedo Xr |
| Dexcom, INC. | $17.97 | 2025 | Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $14.84 | 2023 | Nuzyra |
| Exact Sciences Corporation | $13.63 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.